Cargando…

Double-Blind, Placebo-Controlled, Randomized Study Comparing 0.0003% Calcitriol with 0.1% Tacrolimus Ointments for the Treatment of Endemic Pityriasis Alba

Background. Pityriasis alba (PA) is a frequent cause of consultation in tropical areas due to its chronic course, frequent relapses, and notorious hypopigmented lesions in pediatric dark skin populations. Currently, no treatment is widely accepted. Objective. To assess the efficacy of 0.0003% calcit...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreno-Cruz, Berenice, Torres-Álvarez, Bertha, Hernández-Blanco, Diana, Castanedo-Cazares, Juan Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346967/
https://www.ncbi.nlm.nih.gov/pubmed/22577371
http://dx.doi.org/10.1155/2012/303275
_version_ 1782232252568043520
author Moreno-Cruz, Berenice
Torres-Álvarez, Bertha
Hernández-Blanco, Diana
Castanedo-Cazares, Juan Pablo
author_facet Moreno-Cruz, Berenice
Torres-Álvarez, Bertha
Hernández-Blanco, Diana
Castanedo-Cazares, Juan Pablo
author_sort Moreno-Cruz, Berenice
collection PubMed
description Background. Pityriasis alba (PA) is a frequent cause of consultation in tropical areas due to its chronic course, frequent relapses, and notorious hypopigmented lesions in pediatric dark skin populations. Currently, no treatment is widely accepted. Objective. To assess the efficacy of 0.0003% calcitriol and 0.1% tacrolimus ointments compared with placebo in the treatment of endemic PA. Methods. Twenty-eight children aged 3–17 years with 56 symmetrical lesions and phototype IV-V, were randomly assigned to receive the treatments on target lesions on the face. Improvement was evaluated at baseline and 8 weeks later clinically and by digital quantification of the affected area, colorimetry, and transepidermal water loss (TEWL). Results. Tacrolimus and calcitriol ointments induced a mean improvement of 68%, compared to 44% of placebo. We found an elevated TEWL in PA lesions. In the treated plaques, the reduction of the affected area was associated with improvement of pigmentation and TEWL. Conclusions. Calcitriol and tacrolimus induced similar repigmentation in endemic PA lesions. Melanogenic, anti-inflammatory, and barrier defect restoration properties of these drugs may explain these findings.
format Online
Article
Text
id pubmed-3346967
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33469672012-05-10 Double-Blind, Placebo-Controlled, Randomized Study Comparing 0.0003% Calcitriol with 0.1% Tacrolimus Ointments for the Treatment of Endemic Pityriasis Alba Moreno-Cruz, Berenice Torres-Álvarez, Bertha Hernández-Blanco, Diana Castanedo-Cazares, Juan Pablo Dermatol Res Pract Clinical Study Background. Pityriasis alba (PA) is a frequent cause of consultation in tropical areas due to its chronic course, frequent relapses, and notorious hypopigmented lesions in pediatric dark skin populations. Currently, no treatment is widely accepted. Objective. To assess the efficacy of 0.0003% calcitriol and 0.1% tacrolimus ointments compared with placebo in the treatment of endemic PA. Methods. Twenty-eight children aged 3–17 years with 56 symmetrical lesions and phototype IV-V, were randomly assigned to receive the treatments on target lesions on the face. Improvement was evaluated at baseline and 8 weeks later clinically and by digital quantification of the affected area, colorimetry, and transepidermal water loss (TEWL). Results. Tacrolimus and calcitriol ointments induced a mean improvement of 68%, compared to 44% of placebo. We found an elevated TEWL in PA lesions. In the treated plaques, the reduction of the affected area was associated with improvement of pigmentation and TEWL. Conclusions. Calcitriol and tacrolimus induced similar repigmentation in endemic PA lesions. Melanogenic, anti-inflammatory, and barrier defect restoration properties of these drugs may explain these findings. Hindawi Publishing Corporation 2012 2012-04-22 /pmc/articles/PMC3346967/ /pubmed/22577371 http://dx.doi.org/10.1155/2012/303275 Text en Copyright © 2012 Berenice Moreno-Cruz et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Moreno-Cruz, Berenice
Torres-Álvarez, Bertha
Hernández-Blanco, Diana
Castanedo-Cazares, Juan Pablo
Double-Blind, Placebo-Controlled, Randomized Study Comparing 0.0003% Calcitriol with 0.1% Tacrolimus Ointments for the Treatment of Endemic Pityriasis Alba
title Double-Blind, Placebo-Controlled, Randomized Study Comparing 0.0003% Calcitriol with 0.1% Tacrolimus Ointments for the Treatment of Endemic Pityriasis Alba
title_full Double-Blind, Placebo-Controlled, Randomized Study Comparing 0.0003% Calcitriol with 0.1% Tacrolimus Ointments for the Treatment of Endemic Pityriasis Alba
title_fullStr Double-Blind, Placebo-Controlled, Randomized Study Comparing 0.0003% Calcitriol with 0.1% Tacrolimus Ointments for the Treatment of Endemic Pityriasis Alba
title_full_unstemmed Double-Blind, Placebo-Controlled, Randomized Study Comparing 0.0003% Calcitriol with 0.1% Tacrolimus Ointments for the Treatment of Endemic Pityriasis Alba
title_short Double-Blind, Placebo-Controlled, Randomized Study Comparing 0.0003% Calcitriol with 0.1% Tacrolimus Ointments for the Treatment of Endemic Pityriasis Alba
title_sort double-blind, placebo-controlled, randomized study comparing 0.0003% calcitriol with 0.1% tacrolimus ointments for the treatment of endemic pityriasis alba
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346967/
https://www.ncbi.nlm.nih.gov/pubmed/22577371
http://dx.doi.org/10.1155/2012/303275
work_keys_str_mv AT morenocruzberenice doubleblindplacebocontrolledrandomizedstudycomparing00003calcitriolwith01tacrolimusointmentsforthetreatmentofendemicpityriasisalba
AT torresalvarezbertha doubleblindplacebocontrolledrandomizedstudycomparing00003calcitriolwith01tacrolimusointmentsforthetreatmentofendemicpityriasisalba
AT hernandezblancodiana doubleblindplacebocontrolledrandomizedstudycomparing00003calcitriolwith01tacrolimusointmentsforthetreatmentofendemicpityriasisalba
AT castanedocazaresjuanpablo doubleblindplacebocontrolledrandomizedstudycomparing00003calcitriolwith01tacrolimusointmentsforthetreatmentofendemicpityriasisalba